ArticleFrontiers in endocrinology2026
Pre-treatment serum phosphate as a metabolic correlate of live birth after IVF/ICSI: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oocyte developmental competence is influenced by the systemic metabolic milieu during folliculogenesis. Inorganic phosphate is essential for ATP synthesis, nucleic acid metabolism, and phosphorylation-dependent signalling, but its relationship with assisted reproductive technology outcomes remains unclear. We investigated whether pre-treatment fasting serum phosphate was associated with live birth after first IVF/ICSI fresh embryo transfer. Methods: This retrospective cohort study included 2, 226 women aged 20-42 years undergoing their first IVF/ICSI cycle with fresh embryo transfer between January 2022 and June 2024. Serum phosphate was measured before ovarian stimulation and analysed as quartiles and per 1-SD increase (0.146 mmol/L). Multivariable logistic regression assessed associations with live birth, adjusting for demographic, ovarian reserve, metabolic, and treatment-related factors. Restricted cubic splines evaluated dose-response relationships. Measurement-window analyses stratified participants by the interval between biochemistry assessment and oocyte retrieval. Results: The overall live birth rate was 60%, increasing from 56% in the lowest phosphate quartile to 66% in the highest (P for trend = 0.003). Each 1-SD increase in serum phosphate was associated with higher odds of live birth (adjusted OR 1.15, 95% CI 1.06-1.26; P = 0.002), with a linear dose-response (P for non-linearity = 0.305). Serum phosphate was not associated with MII oocyte count or usable embryo count. In measurement-window analyses, the association was consistent in the 60-120 day window (n = 1, 485; adjusted OR 1.18, 95% CI 1.03-1.35) and the 120-180 day window (n = 637; adjusted OR 1.16, 95% CI 1.01-1.34). The 0-60 day stratum was underpowered (n = 104). Additional adjustment for calcium, alkaline phosphatase, fasting glucose, and trigger-day progesterone did not materially alter the results. Conclusions: Higher pre-treatment serum phosphate was associated with higher odds of live birth after IVF/ICSI, independent of oocyte yield. External validation and mechanistic studies are required before clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.